What is in the vial besides the peptide

The active ingredient is the minority of the contents

A peptide injection is a formulation. The molecule doing the work is dissolved or suspended in a system built around it. That system holds the acidity steady, brings the solution near the salt concentration of body fluid, and in some cases stops organisms growing in it.

Those supporting ingredients are called excipients or inactive ingredients. Inactive means they are not the therapeutic agent. It does not mean they are inert in a person.

For an approved product every one of them is printed in the labeling, by name, with its amount. That makes approved peptide labels the cleanest available window into what an injectable peptide formulation is actually made of.

One product, two formulations, and the difference is the preservative

The tirzepatide product marketed as ZEPBOUND is the clearest example on the market, because it ships in two presentations with two ingredient lists.

The single-dose pen and single-dose vial contain the peptide, sodium chloride, sodium phosphate dibasic heptahydrate and water for injection. Acid or base may be added to set the acidity. That is a buffer, a salt and water.

The multi-dose vial and the multi-use pen contain all of that and three more ingredients: benzyl alcohol, glycerin and phenol. Benzyl alcohol and phenol are antimicrobial preservatives. Glycerin adjusts tonicity.

Same brand, same molecule, same route. The extra ingredients exist because a container that gets entered more than once needs something to stop growth between entries. This is the mechanism behind the whole single-dose and multiple-dose distinction, made visible on one label.

What each class of ingredient is doing

Buffers hold the acidity steady. Peptides degrade faster outside a narrow range, and a label states the target. The semaglutide product marketed as OZEMPIC lists disodium phosphate dihydrate and states an acidity of roughly 7.4.

Tonicity agents keep the solution close to the salt concentration of body fluid, which reduces stinging and tissue irritation. Propylene glycol does that job in OZEMPIC. Glycerin does it in the bremelanotide product marketed as VYLEESI and in the multi-dose tirzepatide presentation.

Preservatives stop microbial growth in a container that is entered repeatedly. Phenol does that in OZEMPIC. Phenol and benzyl alcohol do it together in multi-dose ZEPBOUND.

Bulking agents give a freeze-dried cake something to be. The tesamorelin product marketed as EGRIFTA WR is a preservative-free lyophilized powder, and its inactive ingredients are hydroxypropyl betadex and mannitol. Mannitol is the bulking agent; the betadex is a solubilizing carrier.

Acid and base are added to trim the final acidity. Almost every label above says hydrochloric acid or sodium hydroxide may have been used, which is why those two appear on ingredient lists without appearing in any meaningful quantity.

A preservative is a dating decision

A preservative is not there for the molecule. It is there for the container.

FDA's draft guidance for outsourcing facilities makes the link explicit. For multiple-dose products, appropriate laboratory tests include antimicrobial effectiveness, whether the product contains a preservative or the formulation is inherently hostile to growth. It points at the pharmacopeial chapter on antimicrobial effectiveness for the methods and the acceptance criteria.

Then it states the consequence. If those criteria are met, labeling a multiple-dose product with an in-use period of up to twenty-eight days is considered appropriate, subject to stability testing.

That is where the familiar month-long window on a multiple-dose vial comes from. It is bought by a specific ingredient passing a specific test. A preparation with nothing in it to resist growth has not earned that window and does not get it.

Inactive does not mean harmless, and the labels say so

Benzyl alcohol is the standard illustration, and it has an approved product built around it. Bacteriostatic Water for Injection is water with benzyl alcohol added as a preservative, at either nine or eleven milligrams per milliliter depending on the presentation.

Its label carries a contraindication rather than a caution. Because of the potential toxicity of benzyl alcohol in newborns, solutions containing it must not be used in that population. The warning section adds that data are unavailable on the toxicity of other preservatives in that age group.

The vial itself is printed with the sentence in capitals: not for use in neonates. An inactive ingredient earned a contraindication and a statement on the carton.

Sulfites carry a mandated warning of their own. Federal regulation reaches any prescription drug with a sulfite added as an inactive ingredient, regardless of the amount. Its labeling must bear a specific warning about allergic-type reactions, including anaphylactic symptoms and asthmatic episodes. The rule exists because an antioxidant added to protect the active ingredient turned out to matter to some of the people receiving it.

Two products with the same peptide are not the same product

FDA has a vocabulary for this that is worth borrowing, because it is precise about how small a difference has to be before two formulations count as the same.

Qualitative sameness means the second product uses the same inactive ingredients as the first. Quantitative sameness means the concentrations of those inactive ingredients are within five percent of the first product's. The agency uses both tests when deciding whether a generic injectable can skip a study.

It also names the ingredients most likely to differ. An applicant may seek approval for a parenteral product that differs from the reference in preservative, buffer or antioxidant, provided the differences are identified, characterized, and shown not to affect safety or efficacy.

The lesson transfers. Preservative, buffer and antioxidant are exactly the fields where two vials of the same peptide are most likely to diverge. That divergence is invisible when only the active ingredient is named.

Why this is usually unanswerable for a compounded vial

An approved product carries FDA-approved labeling, and that labeling prints the inactive ingredients. That is why every ingredient named above could be checked against a public document.

A compounded preparation has no approved labeling to read. What exists is the pharmacy's own label and the pharmacy's own records. A buyer's access to the ingredient list therefore depends on the pharmacy being named and on someone asking it.

This is the practical reason the site treats naming the compounding pharmacy as a disclosure worth scoring. The formulation question is one of several that only becomes askable once the maker is identified.

It is also why a preservative-free description is worth noticing rather than skipping. It says something about the container, the in-use window and what has to happen after the seal is broken.

What to look for, and where instructions come from

Look for whether the preparation is described as single-dose or multiple-dose. That is the first fact, and it predicts most of the rest.

Look for the words preservative-free, and for a named preservative if there is one. Benzyl alcohol and phenol are the two that appear on the approved peptide labels cited here.

Look for anything you have reacted to before. Preservatives, sulfites and solubilizing carriers are the ingredients most often behind an injection-site reaction, and they are named on approved labels for that reason.

Your instructions for handling, preparing or administering anything come from your prescriber and from the labeling that arrived with the product. Nothing on this page is one.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. ZEPBOUND (tirzepatide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, August 2026
2. OZEMPIC (semaglutide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, June 2026
3. EGRIFTA WR (tesamorelin) for injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, July 2026
4. Bacteriostatic Water for Injection, USP — FDA-approved prescribing information — National Library of Medicine, DailyMed, May 2026
5. 21 CFR 201.22 — Prescription drugs containing sulfites; required warning statements — Office of the Federal Register, Electronic Code of Federal Regulations, January 2026
6. Draft Guidance on Semaglutide (product-specific guidance, revised) — U.S. Food and Drug Administration, July 2026
7. Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act (draft guidance, revision 2) — U.S. Food and Drug Administration, January 2020